Toxoplasma gondii and Schizophrenia: Linkage Through Astrocyte-Derived Kynurenic Acid?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Toxoplasma gondii is a ubiquitous food- and water-borne parasite that in most individuals is able to persist in multiple tissues, including the central nervous system (CNS), without causing an apparent clinical disease.1 During the chronic phase of toxoplasmosis, the latent stage of the parasite is found in the CNS, and studies from murine models have established that long-term resistance to the parasite is dependent on the ability to generate and maintain parasite-specific CD4+ and CD8+ T cells. Consistent with this observation, patients with primary or acquired defects in T cell–mediated immunity are susceptible to toxoplasmic encephalitis (TE). Indeed, in patients with acquired immunodeficiency syndrome, T. gondii is one of the most common opportunistic infections affecting the CNS. One of the notable features that accompanies T. gondii infection in the CNS is a prominent activation of resident glial cells, in particular astrocytes.2 We propose here that this event may play a causative role in the development of schizophrenia. A considerable body of evidence links T. gondii infection to an increased incidence of schizophrenia.3,4,5,6 However, the association between the parasitic infection and disease, while strong, is so far exclusively correlative in nature. Based on epidemiological data, ie, statistical analyses, the hypothesis has with few exceptions ignored the cellular events and molecular mechanisms by which the infection might promote or precipitate pathophysiology associated with schizophrenia. Recent experiments in our laboratories have provided provocative clues regarding the enigmatic connection between infection and disease etiology. Our collaboration originated from the central role that astrocytes play in the synthesis of kynurenic acid (KYNA), a metabolite of the kynurenine pathway of tryptophan degradation. When present at levels slightly above endogenous brain concentrations, this metabolite can inhibit both N-methyl-D-aspartate (NMDA) and α7 nicotinic acetylcholine (α7nACh) receptors.7 These two receptors are widely purported to have causative links to cognitive processes. Unrelated to antipsychotic medication, KYNA levels are significantly elevated in the brain of individuals with schizophrenia.8 Thus, it follows that abnormally high KYNA levels may contribute to the patients' cognitive impairment. This concept is supported by studies in rodents, which show that experimental elevation of cerebral KYNA levels results in impaired sensory gating.9,10 Furthermore, nanomolar concentrations of KYNA, by blocking presynaptic α7nACh receptors on glutamatergic nerve terminals, have been shown to significantly reduce the extracellular levels of glutamate in rat brain in vivo.11,12 KYNA may thus contribute to the putative hyponicotinergic and hypoglutamatergic tone in schizophrenia.13,14 In view of the proposed link between KYNA and cognitive processes, it is important to understand the biochemical events leading to and regulating its formation and function in the brain. KYNA synthesis is initiated by the oxidative ring opening of tryptophan by indoleamine 2,3-dioxygenase (IDO) and/or tryptophan dioxygenase (TDO). The reaction product of IDO and TDO, kynurenine, is then irreversibly converted to KYNA. In the brain, this transamination takes place almost exclusively in astrocytes, which then rapidly liberate newly produced KYNA into the extracellular milieu, placing the metabolite in an excellent position to influence surrounding neurons.15 Interestingly, the mRNA for tryptophan 2,3-dioxygenase (TDO2) is elevated in the brain of individuals with schizophrenia, and a concomitant increased density of TDO2-immunopositive astroglial cells is seen in the patients' white matter.16 Because TDO is one of the upstream enzymes responsible for the biosynthesis of KYNA, this enhanced expression could conceivably lead to an elevation of KYNA levels in the diseased brain and therefore play a part in the pathophysiology of the disorder. As noted above, astrocyte activation is a prominent feature of TE, but it was not known whether this reaction is associated with a dysregulation of KYNA production. In a first attempt to investigate this possible link, we recently examined the brains of chronically T. gondii–infected animals for signs of impaired kynurenine pathway flux. Indeed, infected mice showed massive astrocyte activation and, concomitantly, a greater than 7-fold increase in the brain content of KYNA.17 Because this effect was accompanied by an increase in the levels of KYNA's bioprecursor kynurenine, these changes are likely due to a stimulation of upstream kynurenine pathway enzymes such as IDO and/or TDO. At present, it is unclear whether this represents a direct response to invading parasites or, as seems more likely, a secondary consequence of the inflammatory response that accompanies the presence of T. gondii in the brain. These results show that T. gondii infection provides an in vivo model system t
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
The tripartite synapse: roles for gliotransmission in health and disease
Halassa, M. M., Fellin, T., & Haydon, P. G. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.12.005 · Cited by 852
Cited by
Verkhratsky, A., & Nedergaard, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2016 · Cited by 1,678
Astrocytes: a central element in neurological diseases
Pekny, M., Pekna, M., Messing, A., Steinhäuser, C., Lee, J.-M., Parpura, V., Hol, E. M., Sofroniew, M. V., & Verkhratsky, A. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1513-1 · Cited by 755
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update
Torrey, E. F., Bartko, J. J., & Yolken, R. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs043 · Cited by 403
(2013) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-53490-3.00008-x · Cited by 335
Metadata
- Authors
- Schwarcz, R., & Hunter, C. A.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-19
- Volume
- 33
- Issue
- 3
- Pages
- 652-653
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2130994002
- Cited by
- 116
- References
- 2
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.